Tyra Biosciences priced a $400M offering to fund dabogratinib trials in bladder cancer and achondroplasia. See the deal and ...

Cardiff Oncology and Nerviano settle the onvansertib license dispute ahead of a planned Phase III trial. Read the latest deal ...

Lipocine launches a second Phase III trial of LPCN 1154 for postpartum depression after the first missed its endpoint. Read ...

Revelyx Bio’s YY003 clears Phase II testing as a potential first recombinant, ready-to-use botulinum toxin. Read the latest ...

Santa Ana Bio begins first-in-human testing of SAB01, a bispecific antibody targeting mast cells for autoimmune and ...

China approves Walvax’s JN.1-targeted mRNA COVID-19 vaccine for adults. Explore the vaccine’s regulatory milestone and ...

MRI surveillance alone improved cognition and reduced serious side effects versus PCI in SCLC, new Phase III MAVERICK results ...

The FDA approved Isembyld for SMA patients aged 2 and older on SMN2-targeted therapy. Read what the first muscle-targeted ...

Enhertu reduced progression or death risk by 37% in first-line HER2-mutant lung cancer. See what DESTINY-Lung04 results mean ...

AstraZeneca’s camizestrant misses the SERENA-4 Phase III endpoint in first-line breast cancer. See what the setback means for ...

The FDA approved Joenja for children ages 4 to 11 with APDS, making it the first treatment for this group. See what the ...

GenSci registers a Phase I trial of GenSci148 for nAMD, DME and RVO. Discover how the four-target fusion protein could ...